Researchers, research funders and policymakers should give greater voice to the risks and harms associated with particular cannabis policies and to the evaluation of alternative regulatory frameworks. Given the decades of research and experience with cannabis prohibition, it seems reasonable to reorient the cannabis policy debate based on known policy-attributable harms rather than to continue to speculate on questions of causality between cannabis use and mental illnesses such as psychosis, depression, and related disorders, that will not be definitively answered any time soon
Cannabis dependence is a disorder primarily experienced by young adults, especially in higher income countries. It has not been shown to increase mortality as opioid and other forms of illicit drug dependence do. Our estimates suggest that cannabis use as a risk factor for schizophrenia is not a major contributor to population-level disease burden.
Robin Room, Peter Reuter (RAND), Wayne Hall, Benedikt Fischer, Simon Lenton, Amanda Fielding
01 September 2008
Despite cannabis being the most widely used illegal drug, and therefore the mainstay of the ‘war on drugs’, it has only ever held a relatively marginal position in international drug policy discussions. Amanda Fielding of the Beckley Foundation decided to convene a team of the world’s leading drug policy analysts to prepare an overview of the latest scientific evidence surrounding cannabis and the policies that control its use. The report of the Beckley Foundation's Global Cannabis Commission is aimed at bringing cannabis to the attention of policymakers and guide decision making.